Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
Miromatrix Medical Inc. (NASDAQ: MIRO) announced that CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 28-29, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (NASDAQ: MIRO) announced that CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 28-29, 2022. The event focuses on advancements in kidney transplants on the first day and innovations in hematopoietic stem cell transplants on the second. Ross's presentation is scheduled for September 28 at 10:00 am CT. Miromatrix specializes in bioengineering fully transplantable organs, particularly focusing on human livers and kidneys to address organ shortages.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was +2.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event. The two-day virtual event held this year on September 28-29, will focus the first day on solid organ transplant (SOT), in particular, kidney transplants, and the second day on the unmet need and innovations in hematopoietic stem cell transplant (HSCT).
Mr. Ross will be presenting at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 28th, 2022 at 10:00 am CT. Registration for the event can be found here.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.